Acrobiosystems Co.,Ltd.

SZSE:301080 Stock Report

Market Cap: CN¥5.3b

AcrobiosystemsLtd Past Earnings Performance

Past criteria checks 1/6

AcrobiosystemsLtd has been growing earnings at an average annual rate of 7.6%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 22.6% per year. AcrobiosystemsLtd's return on equity is 4.1%, and it has net margins of 18.3%.

Key information

7.6%

Earnings growth rate

-2.3%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate22.6%
Return on equity4.1%
Net Margin18.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

AcrobiosystemsLtd's (SZSE:301080) Anemic Earnings Might Be Worse Than You Think

Nov 06
AcrobiosystemsLtd's (SZSE:301080) Anemic Earnings Might Be Worse Than You Think

AcrobiosystemsLtd's (SZSE:301080) Weak Earnings Might Be Worse Than They Appear

May 02
AcrobiosystemsLtd's (SZSE:301080) Weak Earnings Might Be Worse Than They Appear

Recent updates

AcrobiosystemsLtd's (SZSE:301080) Anemic Earnings Might Be Worse Than You Think

Nov 06
AcrobiosystemsLtd's (SZSE:301080) Anemic Earnings Might Be Worse Than You Think

Investors Appear Satisfied With Acrobiosystems Co.,Ltd.'s (SZSE:301080) Prospects As Shares Rocket 27%

Oct 01
Investors Appear Satisfied With Acrobiosystems Co.,Ltd.'s (SZSE:301080) Prospects As Shares Rocket 27%

Why We're Not Concerned About Acrobiosystems Co.,Ltd.'s (SZSE:301080) Share Price

Jul 15
Why We're Not Concerned About Acrobiosystems Co.,Ltd.'s (SZSE:301080) Share Price

AcrobiosystemsLtd's (SZSE:301080) Weak Earnings Might Be Worse Than They Appear

May 02
AcrobiosystemsLtd's (SZSE:301080) Weak Earnings Might Be Worse Than They Appear

Revenue & Expenses Breakdown

How AcrobiosystemsLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:301080 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24595109302150
30 Jun 24575119287140
31 Mar 24553139272130
31 Dec 23544154255122
30 Sep 23534166242119
30 Jun 23514186227123
31 Mar 23497195204120
01 Jan 23474204186112
30 Sep 22461219169107
30 Jun 2243821114684
31 Mar 2241018713170
01 Jan 2238517411760
30 Sep 213511598749
30 Jun 213221467344
31 Mar 212861356437
31 Dec 202461165731
31 Dec 19103115720
31 Dec 1870113417
31 Dec 174772510

Quality Earnings: 301080 has a high level of non-cash earnings.

Growing Profit Margin: 301080's current net profit margins (18.3%) are lower than last year (31.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 301080's earnings have grown by 7.6% per year over the past 5 years.

Accelerating Growth: 301080's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 301080 had negative earnings growth (-34.4%) over the past year, making it difficult to compare to the Biotechs industry average (1.3%).


Return on Equity

High ROE: 301080's Return on Equity (4.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 01:42
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Acrobiosystems Co.,Ltd. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pei ChengChina Galaxy Securities Co., Ltd.
Yuan GaoChina International Capital Corporation Limited
Jiaying FuChina International Capital Corporation Limited